Search results
AstraZeneca and Daiichi Sankyo’s ADC improves survival in NSCLC trial
Clinical Trials Arena via Yahoo Finance· 12 hours agoAstraZeneca and Daiichi Sankyo have reported high-level overall survival (OS) results from the Phase...
AstraZeneca, Daiichi Sankyo's Experimental Lung Cancer Drug Shows Improvement in Patients
Market Watch· 11 hours agoAstraZeneca said its experimental drug for non-small cell lung cancer, jointly developed with Japan's Daiichi Sankyo, showed improvement in progression-free survival in its ...
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
Zacks via Yahoo Finance· 8 hours agoWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the...
AstraZeneca aims for $80 bln in total revenue by 2030
Reuters· 7 days ago, opens new tab aims to grow revenue by about 75% to $80 billion by 2030, it said on Tuesday,...
AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by Kingsview Wealth Management LLC
ETF DAILY NEWS· 6 days agoKingsview Wealth Management LLC grew its stake in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 11.3% during the 4th quarter, according to the company in its most recent disclosure ...
AstraZeneca, Merck, GSK Struck Record $44.1B Licensing Deals With Chinese Drugmakers In 2023: Report...
Benzinga· 11 hours agoWestern pharmaceutical companies and investors are driving a record number of licensing deals with...
AstraZeneca Targets $80 Billion Revenue by 2030 Through Pipeline Expansion
The Wall Street Journal· 7 days agoAstraZeneca has set out a new revenue target as it aims to bolster its investment in technologies...
Here's Why We Think AstraZeneca (LON:AZN) Is Well Worth Watching
Simply Wall St. via Yahoo Finance· 3 days agoIf this kind of company isn't your style, you like companies that generate revenue, and even earn...
AstraZeneca kicks off ‘new era of growth’ with $80 billion sales goal by 2030
Market Watch· 7 days agoThe Anglo-Swedish pharmaceutical company’s CEO Pascal Soriot said the announcement marks the start...
Pharma Stock Roundup: AZN's 2030 Sales Target, PFE's New Cost Cut Plan & More
Zacks via Yahoo Finance· 3 days agoAstraZeneca (AZN) announces an ambitious target of achieving $80 billion in revenues by 2030. Pfizer...